PD
LBRX

Point72 (DIFC)’s LB Pharmaceuticals LBRX Stock Holding History

Point72 (DIFC)’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$537K Buy
+34,003
New +$540K 0.04% 268

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Point72 (DIFC)'s LBRX Position: Q3 2025 in Review

Point72 (DIFC) opened a new position in LB Pharmaceuticals (LBRX) in Q3 2025: 34,003 shares worth $537K. The stake represents 0.04% of the portfolio and ranks #268 among its holdings.

53 funds tracked by Wall St. Rank hold LBRX as of Q3 2025.

  • Point72 (DIFC) held 34,003 shares of LB Pharmaceuticals worth $537K as of Q3 2025.
  • LB Pharmaceuticals was a new Point72 (DIFC) position in Q3 2025.
  • LB Pharmaceuticals made up 0.04% of Point72 (DIFC)'s portfolio in Q3 2025, its #268 holding.
  • 53 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.